Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria
- 1 July 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (1), 63-72
- https://doi.org/10.1002/cpt.1802
Abstract
Givosiran is a small interfering ribonucleic acid agent that was recently approved in the United States for the treatment of acute hepatic porphyria (AHP). This phase I study evaluated the safety, pharmacokinetic, and pharmacodynamic profile of subcutaneously (SC) administered givosiran in patients with acute intermittent porphyria, the most common AHP type. Givosiran was rapidly absorbed from the SC injection site with peak plasma concentrations achieved within 0.5-5 hours followed by elimination with a short half-life of 4-10 hours. Plasma exposures of AS(N-1)3 ' givosiran, an active metabolite with equal potency as givosiran, was 35%-75%. Givosiran treatment resulted in a rapid and dose-dependent reduction in urinary aminolevulinic acid (ALA) and porphobilinogen (PBG) towards the upper limit of normal (ULN) in AHP patients. Greater and more sustained reductions in ALA and PBG were achieved with once monthly dosing compared with once quarterly dosing. After monthly dosing, trough ALA levels were reduced to below the ULN, approximately 95% reduction from baseline, at both the 2.5 and 5.0 mg/kg doses.Funding Information
- Alnylam Pharmaceuticals
This publication has 20 references indexed in Scilit:
- Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA QuantificationMolecular Therapy Nucleic Acids, 2015
- Role of Delta-aminolevulinic Acid in the Symptoms of Acute PorphyriaThe American Journal of Medicine, 2014
- Acute Porphyrias in the USA: Features of 108 Subjects from Porphyrias ConsortiumThe American Journal of Medicine, 2014
- Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyriaJournal of Clinical Pathology, 2013
- A status report on RNAi therapeuticsSilence, 2010
- RNAi therapeutics: a potential new class of pharmaceutical drugsNature Chemical Biology, 2006
- Variations in Porphobilinogen and 5-Aminolevulinic Acid Concentrations in Plasma and Urine from Asymptomatic Carriers of the Acute Intermittent Porphyria Gene with Increased Porphyrin Precursor ExcretionClinical Chemistry, 2006
- Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAsNature, 2004
- Prognosis of Acute ProphyriaMedicine, 1992
- The Role of Surface Carbohydrates in the Hepatic Recognition and Transport of Circulating GlycoproteinsPublished by Wiley ,1974